PTENgenomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity
Open Access
- 22 November 2012
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 12 (1), 543
- https://doi.org/10.1186/1471-2407-12-543
Abstract
Prostate cancer (PCa), a leading cause of cancer death in North American men, displays a broad range of clinical outcome from relatively indolent to lethal metastatic disease. Several genomic alterations have been identified in PCa which may serve as predictors of progression. PTEN, (10q23.3), is a negative regulator of the phosphatidylinositol 3-kinase (PIK3)/AKT survival pathway and a tumor suppressor frequently deleted in PCa. The androgen receptor (AR) signalling pathway is known to play an important role in PCa and its blockade constitutes a commonly used treatment modality. In this study, we assessed the deletion status of PTEN along with AR expression levels in 43 primary PCa specimens with clinical follow-up. Fluorescence In Situ Hybridization (FISH) was done on formalin fixed paraffin embedded (FFPE) PCa samples to examine the deletion status of PTEN. AR expression levels were determined using immunohistochemistry (IHC). Using FISH, we found 18 cases of PTEN deletion. Kaplan-Meier analysis showed an association with disease recurrence (P=0.03). Concurrently, IHC staining for AR found significantly lower levels of AR expression within those tumors deleted for PTEN (PPTEN deleted. We confirmed the predictive value of PTEN deletion in disease recurrence (P=0.03). PTEN deletion was also linked to diminished expression of PTEN (PP=0.02). Furthermore, gene set enrichment analysis revealed a diminished expression of genes downstream of AR signalling in PTEN deleted tumors. Altogether, our data suggest that PTEN deleted tumors expressing low levels of AR may represent a worse prognostic subset of PCa establishing a challenge for therapeutic management.Keywords
This publication has 41 references indexed in Scilit:
- High‐resolution array CGH identifies novel regions of genomic alteration in intermediate‐risk prostate cancerThe Prostate, 2009
- PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancerThe Journal of Pathology, 2009
- Mechanisms mediating androgen receptor reactivation after castrationUrologic Oncology: Seminars and Original Investigations, 2009
- Is PTEN loss associated with clinical outcome measures in human prostate cancer?British Journal of Cancer, 2008
- Genomic Profiling Reveals Alternative Genetic Pathways of Prostate TumorigenesisCancer Research, 2007
- The emerging role of the PI3-K-Akt pathway in prostate cancer progressionProstate Cancer and Prostatic Diseases, 2005
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerThe New England Journal of Medicine, 2004
- Pten Dose Dictates Cancer Progression in the ProstatePLoS Biology, 2003
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998
- Androgen receptors in prostate cancerJournal of Endocrinology, 1996